4:30 PM ET
8-K
Business Update
Novavax Business Update
Novavax earned a $125 million milestone payment from Sanofi following the dosing of the fifth patient in a Phase 3 influenza-COVID-19 combination vaccine trial in the European Union. The trial utilizes Novavax's Nuvaxovid COVID-19 component in combination with Sanofi's high-dose flu vaccine. Novavax expects to receive the payment by the first quarter of 2027 and remains eligible for further clinical and regulatory milestones.
- Counterparty
- Sanofi Pasteur Inc.